Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Frattarelli DA, Galinkin JL, Green TP, Hudak ML, Neville KA, Paul IM, Van Den Anker JN, Hegenbarth M, Hudak ML, Knight M, Shaddy RE, Snodgrass WR, Alexander JJ, Chescheir NC, Cragan JD, Rieder MJ, Robb A, Sachs HC, Zajicek A, Giacoia GP, Del Monte M, Koteras RJ, Papile LA, Baley JE, Bhutani VK, Carlo WA, Cummings JJ, Kumar P, Polin RA, Tan RC, Wang KS, Watterberg KL, Adamkin DH, Barfield WD, Macones G, Jefferies AL, Mainous RO, Raju TN, Barth WH Jr, Couto J.
Maternal use of certain drugs during pregnancy can result in transient neonatal signs consistent with withdrawal or acute toxicity or cause sustained signs consistent with a lasting drug effect. In addition, hospitalized infants who are treated with opioids or benzodiazepines to provide analgesia or sedation may be at risk for manifesting signs of withdrawal. This statement updates information about the clinical presentation of infants exposed to intrauterine drugs and the therapeutic options for treatment of withdrawal and is expanded to include evidence-based approaches to the management of the hospitalized infant who requires weaning from analgesics or sedatives.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on